IMPEDIMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 AUD | 0.00% |
|
-6.98% | -44.83% |
| Apr. 30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
| Apr. 30 | Transcript : ImpediMed Limited, Q3 2024 Earnings Call, Apr 30, 2024 |
Valuation
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 43.68 | 62.11 | 156.6 | 108.5 | 390.9 | 161.8 | - | - |
| Enterprise Value (EV) 1 | 32.35 | 43.31 | 137.4 | 67.9 | 346.7 | 137.4 | 148.7 | 151.7 |
| P/E ratio | -1.92 x | -1.55 x | -5.25 x | -6.1 x | -18 x | -8.09 x | -12.6 x | -83.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.4 x | 10.8 x | 18.6 x | 10.3 x | 34.5 x | 14.9 x | 8.45 x | 5 x |
| EV / Revenue | 7.7 x | 7.54 x | 16.3 x | 6.43 x | 30.6 x | 12.7 x | 7.76 x | 4.68 x |
| EV / EBITDA | -1.37 x | -2.17 x | -7.24 x | -3.98 x | -18.4 x | -7.35 x | -13.5 x | 143 x |
| EV / FCF | - | -2.24 x | -8.74 x | -3.25 x | -14.4 x | -5.89 x | -8.72 x | -152 x |
| FCF Yield | - | -44.6% | -11.4% | -30.8% | -6.95% | -17% | -11.5% | -0.66% |
| Price to Book | 2.76 x | 2.27 x | 6.14 x | 2.12 x | 5.97 x | 4.46 x | 6.58 x | 7.06 x |
| Nbr of stocks (in thousands) | 379,804 | 1,001,697 | 1,491,679 | 1,777,967 | 2,171,814 | 2,023,094 | - | - |
| Reference price 2 | 0.1150 | 0.0620 | 0.1050 | 0.0610 | 0.1800 | 0.0800 | 0.0800 | 0.0800 |
| Announcement Date | 7/31/19 | 8/25/20 | 8/24/21 | 8/28/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.201 | 5.741 | 8.409 | 10.57 | 11.34 | 10.85 | 19.15 | 32.4 |
| EBITDA 1 | -23.63 | -19.93 | -18.98 | -17.08 | -18.79 | -18.7 | -11.02 | 1.063 |
| EBIT 1 | -24.32 | -21.37 | -20.68 | -19.85 | -21.26 | -21.11 | -13.9 | -2.238 |
| Operating Margin | -578.81% | -372.2% | -245.87% | -187.83% | -187.39% | -194.56% | -72.56% | -6.91% |
| Earnings before Tax (EBT) 1 | -23.94 | -21.33 | -20.67 | -19.83 | -20.49 | -19.8 | -11.85 | 1.65 |
| Net income 1 | -24.12 | -21.38 | -20.71 | -19.87 | -20.52 | -21.13 | -14.45 | -1.947 |
| Net margin | -574.22% | -372.36% | -246.24% | -188.09% | -180.9% | -194.7% | -75.46% | -6.01% |
| EPS 2 | -0.0600 | -0.0400 | -0.0200 | -0.0100 | -0.0100 | -0.009890 | -0.006370 | -0.000960 |
| Free Cash Flow 1 | - | -19.31 | -15.72 | -20.88 | -24.09 | -23.35 | -17.05 | -1 |
| FCF margin | - | -336.34% | -186.88% | -197.66% | -212.38% | -215.21% | -89.03% | -3.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 7/31/19 | 8/25/20 | 8/24/21 | 8/28/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2021 S1 | 2021 S2 | 2022 S1 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|
| Net sales | - | - | 5.196 | - | - |
| EBITDA 1 | - | -9.395 | - | - | -8.836 |
| EBIT | - | -10.25 | - | - | - |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | -8.901 | - | - |
| Net income | -10.44 | - | -8.92 | -10.82 | - |
| Net margin | - | - | -171.67% | - | - |
| EPS | -0.0100 | - | -0.0100 | -0.0100 | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/21/21 | 8/24/21 | 2/24/22 | 2/23/23 | 8/30/23 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 11.3 | 18.8 | 19.2 | 40.6 | 44.3 | 24.4 | 13.1 | 10.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -19.3 | -15.7 | -20.9 | -24.1 | -23.4 | -17.1 | -1 |
| ROE (net income / shareholders' equity) | -93% | -99.1% | -78.3% | -51.9% | -36.7% | -47.3% | -37.3% | 13% |
| ROA (Net income/ Total Assets) | -74.8% | -76.8% | -61.6% | -42.8% | -32.2% | -47.8% | -35.4% | 10.1% |
| Assets 1 | 32.25 | 27.82 | 33.63 | 46.45 | 63.72 | 44.24 | 40.82 | -19.28 |
| Book Value Per Share 2 | 0.0400 | 0.0300 | 0.0200 | 0.0300 | 0.0300 | 0.0200 | 0.0100 | 0.0100 |
| Cash Flow per Share 2 | -0.0500 | -0.0300 | -0.0100 | -0.0100 | -0.0100 | -0.0100 | -0.0100 | 0 |
| Capex 1 | 0.03 | 0.09 | 0.07 | 0.06 | 0.39 | 1.79 | 1.55 | 2.57 |
| Capex / Sales | 0.81% | 1.59% | 0.78% | 0.57% | 3.46% | 16.48% | 8.11% | 7.93% |
| Announcement Date | 7/31/19 | 8/25/20 | 8/24/21 | 8/28/22 | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.08
AUD
Average target price
0.1753
AUD
Spread / Average Target
+119.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.83% | 107M | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| +26.03% | 107B | |
| -1.33% | 62.38B | |
| +11.80% | 51.37B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B |
- Stock Market
- Equities
- IPD Stock
- Financials ImpediMed Limited
